Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

Risk of childhood mortality associated with death of a mother in low-and-middle-income countries: a systematic review and meta-analysis.

Nguyen DTN, Hughes S, Egger S, LaMontagne DS, Simms K, Castle PE, Canfell K.

BMC Public Health. 2019 Oct 11;19(1):1281. doi: 10.1186/s12889-019-7316-x.

2.

Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.

Castle PE, Burk RD, Massad LS, Eltoum IE, Hall CB, Hessol NA, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Colie C, Rahangdale L, Fischl MA, Palefsky JM, Strickler HD.

Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693. [Epub ahead of print]

PMID:
31577842
3.

An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria.

Knapp GC, Sharma A, Olopade B, Alatise OI, Olasehinde O, Arije OO, Castle PE, Kingham TP.

World J Surg. 2019 Nov;43(11):2674-2680. doi: 10.1007/s00268-019-05100-0.

PMID:
31407091
4.

Viral coinfection analysis using a MinHash toolkit.

Dawson ET, Wagner S, Roberson D, Yeager M, Boland J, Garrison E, Chanock S, Schiffman M, Raine-Bennett T, Lorey T, Castle PE, Mirabello L, Durbin R.

BMC Bioinformatics. 2019 Jul 12;20(1):389. doi: 10.1186/s12859-019-2918-y.

5.

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.

Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD, Grewal KK, Locke A, Kinney W, Lorey TS.

JAMA Intern Med. 2019 Jul 1;179(7):881-888. doi: 10.1001/jamainternmed.2019.0306. Erratum in: JAMA Intern Med. 2019 Jul 1;179(7):1007.

6.

Towards global elimination of cervical cancer in all groups of women - Authors' reply.

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K.

Lancet Oncol. 2019 May;20(5):e239. doi: 10.1016/S1470-2045(19)30236-0. No abstract available.

PMID:
31044714
7.

FightHPV: Design and Evaluation of a Mobile Game to Raise Awareness About Human Papillomavirus and Nudge People to Take Action Against Cervical Cancer.

Ruiz-López T, Sen S, Jakobsen E, Tropé A, Castle PE, Hansen BT, Nygård M.

JMIR Serious Games. 2019 Apr 8;7(2):e8540. doi: 10.2196/games.8540.

8.

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Velentzis LS, Smith MA, Simms KT, Lew JB, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Brotherton JML, Skinner R, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland SM, Guy R, Hammond I, Grogan P, Arbyn M, Castle PE, Saville M, Armstrong BK, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):465-471. doi: 10.1016/j.ygyno.2018.12.019.

PMID:
30876490
9.

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.

Landy R, Schiffman M, Sasieni PD, Cheung LC, Katki HA, Rydzak G, Wentzensen N, Poitras NE, Lorey T, Kinney WK, Castle PE.

Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32268. [Epub ahead of print]

PMID:
30861114
10.

Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K.

Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19.

PMID:
30795950
11.

A mobile-phone based high-resolution microendoscope to image cervical precancer.

Grant BD, Quang T, Possati-Resende JC, Scapulatempo-Neto C, de Macedo Matsushita G, Mauad EC, Stoler MH, Castle PE, Guerreiro Fregnani JHT, Schmeler KM, Richards-Kortum R.

PLoS One. 2019 Feb 6;14(2):e0211045. doi: 10.1371/journal.pone.0211045. eCollection 2019.

12.

The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador.

Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, Masch R, Cremer M, Kim JJ.

Int J Gynaecol Obstet. 2019 Apr;145(1):40-46. doi: 10.1002/ijgo.12773.

PMID:
30702142
13.

(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention.

Castle PE, Pierz A.

Obstet Gynecol Clin North Am. 2019 Mar;46(1):107-123. doi: 10.1016/j.ogc.2018.09.007. Review.

PMID:
30683258
14.

Social contexts as mediator of risk behaviors in Rwandan men who have sex with men (MSM): Implications for HIV and STI transmission.

Adedimeji A, Sinayobye JD, Asiimwe-Kateera B, Chaudhry J, Buzinge L, Gitembagara A, Murenzi G, Mugenzi P, Patel VV, Castle PE, Mutesa L, Palefsky J, Anastos KM.

PLoS One. 2019 Jan 18;14(1):e0211099. doi: 10.1371/journal.pone.0211099. eCollection 2019.

15.

Participation in Cervical Screening by Self-collection, Pap, or a Choice of Either in Brazil.

Castle PE, Silva VRS, Consolaro MEL, Kienen N, Bittencourt L, Pelloso SM, Partridge EE, Pierz A, Dartibale CB, Uchimura NS, Scarinci IC.

Cancer Prev Res (Phila). 2019 Mar;12(3):159-170. doi: 10.1158/1940-6207.CAPR-18-0419. Epub 2019 Jan 16.

PMID:
30651294
16.

Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Poitras NE, Lorey TS, Katki HA, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Dec 21. doi: 10.1093/jnci/djy192. [Epub ahead of print]

PMID:
30576462
17.

Five-year prospective evaluation of cytology, HPV testing, and biomarkers for detection of anal precancer in HIV+ MSM.

Clarke MA, Cheung LC, Lorey T, Hare B, Landy R, Tokugawa D, Gage JC, Darragh TM, Castle PE, Wentzensen N.

Clin Infect Dis. 2018 Nov 12. doi: 10.1093/cid/ciy970. [Epub ahead of print]

PMID:
30418518
18.

Perceived Susceptibility to Cervical Cancer among African American Women in the Mississippi Delta: Does Adherence to Screening Matter?

Gibson EG, Gage JC, Castle PE, Scarinci IC.

Womens Health Issues. 2019 Jan - Feb;29(1):38-47. doi: 10.1016/j.whi.2018.09.006. Epub 2018 Nov 3.

PMID:
30401612
19.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.

Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N.

JAMA Oncol. 2019 Feb 1;5(2):181-186. doi: 10.1001/jamaoncol.2018.4270.

20.

Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, Wentzensen N, Strickler HD, Burger EA, Schiffman M.

Prev Med. 2019 Jan;118:44-50. doi: 10.1016/j.ypmed.2018.10.001. Epub 2018 Oct 11.

PMID:
30316878
21.

Anatomical location, sex, and age influence murine arterial circumferential cyclic strain before and during dobutamine infusion.

Castle PE, Scheven UM, Crouch AC, Cao AA, Goergen CJ, Greve JM.

J Magn Reson Imaging. 2019 Jan;49(1):69-80. doi: 10.1002/jmri.26232. Epub 2018 Oct 6.

22.

Reply to M. Swanson et al.

Jeronimo J, Temin S, Castle PE, Shastri SS.

J Glob Oncol. 2018 Sep;4:1-2. doi: 10.1200/JGO.17.00049. Epub 2017 Jul 17. No abstract available.

23.

Protocol for the study of cervical cancer screening technologies in HIV-infected women living in Rwanda.

Murenzi G, Dusingize JC, Rurangwa T, Sinayobye JD, Munyaneza A, Murangwa A, Zawadi T, Hebert T, Mugenzi P, Adedimeji A, Mutesa L, Anastos K, Castle PE.

BMJ Open. 2018 Aug 5;8(8):e020432. doi: 10.1136/bmjopen-2017-020432.

24.

Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report.

Pantano N, Hunt B, Schwarz RA, Parra S, Cherry K, Possati-Resende JC, Longatto-Filho A, Fregnani JHTG, Castle PE, Schmeler K, Richards-Kortum R.

Photochem Photobiol. 2018 Nov;94(6):1308-1313. doi: 10.1111/php.12976. Epub 2018 Jul 31.

25.

Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador.

Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, Soler M, Conzuelo-Rodriguez G, Gage JC, Alonzo TA, Castle PE, Felix JC, Cremer M.

Prev Med. 2018 Sep;114:149-155. doi: 10.1016/j.ypmed.2018.06.017. Epub 2018 Jun 26.

26.

Cervical Cancer Screening among Underscreened and Unscreened Brazilian Women: Training Community Health Workers to be Agents of Change.

Kienen N, Bittencourt L, Pelloso SM, Consolaro ME, Castle PE, Partridge EE, Silva NR, Scarinci IC.

Prog Community Health Partnersh. 2018;12(1S):111-119. doi: 10.1353/cpr.2018.0026.

PMID:
29755054
27.

Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Yu K, Hyun N, Fetterman B, Lorey T, Raine-Bennett TR, Zhang H, Stamps RE, Poitras NE, Wheeler W, Befano B, Gage JC, Castle PE, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Nov 1;110(11):1222-1228. doi: 10.1093/jnci/djy044.

28.

Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study.

In H, Langdon-Embry M, Gordon L, Schechter CB, Wylie-Rosett J, Castle PE, Margaret Kemeny M, Rapkin BD.

J Surg Res. 2018 Jul;227:246-256. doi: 10.1016/j.jss.2018.02.053. Epub 2018 Apr 3.

29.

Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with In Vivo Microscopy: A Cluster-Randomized Community Trial.

Hunt B, Fregnani JHTG, Schwarz RA, Pantano N, Tesoni S, Possati-Resende JC, Antoniazzi M, de Oliveira Fonseca B, de Macêdo Matsushita G, Scapulatempo-Neto C, Kerr L, Castle PE, Schmeler K, Richards-Kortum R.

Cancer Prev Res (Phila). 2018 Jun;11(6):359-370. doi: 10.1158/1940-6207.CAPR-17-0265. Epub 2018 Apr 4.

30.

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, Schnall MD, Skinner CS, Tosteson ANA, Weaver DL, Vachani A, Mehta SJ, Rendle KA, Fedewa SA, Corley DA, Armstrong K.

CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30.

31.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

32.

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

Castle PE, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry Steering Committee.

Prev Med. 2018 Jun;111:177-179. doi: 10.1016/j.ypmed.2018.03.011. Epub 2018 Mar 14.

33.

Charting the Future of Cancer Health Disparities Research-Letter.

Castle PE.

Cancer Res. 2018 Apr 1;78(7):1883-1885. doi: 10.1158/0008-5472.CAN-17-2932. Epub 2018 Mar 5. No abstract available.

34.

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.

Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM, Chen J, Gage JC, Befano B, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Wentzensen N, Schiffman M.

J Clin Microbiol. 2018 Apr 25;56(5). pii: e01910-17. doi: 10.1128/JCM.01910-17. Print 2018 May.

35.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

36.

Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women.

Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, Lorey T, Poitras N, Raine-Bennett TR, Castle PE, Wentzensen N, Burk RD.

Clin Cancer Res. 2018 May 1;24(9):2194-2202. doi: 10.1158/1078-0432.CCR-17-3251. Epub 2018 Feb 2.

37.

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700. Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1.

38.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

39.

Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.

Leinonen MK, Schee K, Jonassen CM, Lie AK, Nystrand CF, Rangberg A, Furre IE, Johansson MJ, Tropé A, Sjøborg KD, Castle PE, Nygård M.

J Clin Virol. 2018 Feb - Mar;99-100:22-30. doi: 10.1016/j.jcv.2017.12.008. Epub 2017 Dec 21.

40.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
41.

Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis.

Taxa L, Jeronimo J, Alonzo TA, Gage J, Castle PE, Cremer ML, Felix JC.

J Low Genit Tract Dis. 2018 Jan;22(1):27-30. doi: 10.1097/LGT.0000000000000355.

42.

A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.

Castle PE, Pierz A, Stoler MH.

Gynecol Oncol. 2018 Feb;148(2):422-429. doi: 10.1016/j.ygyno.2017.12.001. Epub 2017 Dec 14. Review.

PMID:
29248196
43.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

44.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
45.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

46.

Anal Cancer Risk Among People With HIV Infection in the United States.

Colón-López V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, Pfeiffer RM, Engels EA.

J Clin Oncol. 2018 Jan 1;36(1):68-75. doi: 10.1200/JCO.2017.74.9291. Epub 2017 Nov 15.

47.

Smoking and subsequent human papillomavirus infection: a mediation analysis.

Eldridge RC, Pawlita M, Wilson L, Castle PE, Waterboer T, Gravitt PE, Schiffman M, Wentzensen N.

Ann Epidemiol. 2017 Nov;27(11):724-730.e1. doi: 10.1016/j.annepidem.2017.10.004. Epub 2017 Oct 17.

48.

Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, Luciani S, Murokora D, Ngoma T, Qiao Y, Quinn M, Sankaranarayanan R, Sasieni P, Schmeler KM, Shastri SS.

J Glob Oncol. 2016 Oct 12;3(5):635-657. doi: 10.1200/JGO.2016.006577. eCollection 2017 Oct.

49.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

50.

Correspondence regarding Suba et al., human papillomavirus screening for low and middle-income countries.

Castle PE.

Prev Med. 2017 Dec;105:356. doi: 10.1016/j.ypmed.2017.06.030. Epub 2017 Sep 19. No abstract available.

PMID:
28939142

Supplemental Content

Loading ...
Support Center